20,350
-0.49%
Close of 9 Nov 2026, in KRW
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Samjin Pharmaceutical Co
Its shares trade on KRX under the ticker 005500.KS. It has been listed since 18 June 1988. In the fiscal year to 31 December 2025, it reported revenue of ₩309.13bn and net income of ₩24.17bn. At that date it held total assets of ₩470.53bn and shareholders' equity of ₩290.39bn.
Samjin Pharmaceutical Co., Ltd. engages in the manufacture, distribution, and sale of pharmaceutical products. The company is headquartered in Seoul, Seoul. The Company’s products include antipyretics, analgesics, antiphlogistic agents, osteoarthritis agents, osteopathic agents, antihistaminic agents, circulatory system drugs, gastrointestinal agents, osteoporosis treatments, hepatic disease agents, respiratory agents, antibiotics agents, detoxifying agents, antifungal agents, antineoplastic agents and others. Its products are provided in the forms of tablets, injections, capsules and others. The company distributes its products to the hospitals and drugstores. The firm supplies its products within domestic market and to overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 18 Jun 1988
- Employees
- 776
- Website
- samjinpharm.co.kr ↗
Leadership
Pay as last reported
- Mr. Ui Hwan ChoCo-Chairman, since 2021₩1.02bn
- Mr. Seung Ju ChoiCo-Chairman, since 2021₩1.02bn
- Mr. Yong Ju ChoiCo-President, Co-Chief Executive Officer, Director₩537.5m
- Mr. Hong Sun JangCo-President, Co-Chief Executive Officer, Director₩537.5m
- Mr. Hyeon Nam MyungVice President, since 2021
- Mr. Gyu Seok ChoManaging Director
- Ms. Ji Hyeon ChoiManaging Director
- Ms. Jae Rang SungManaging Director
- Mr. Jeong Tae AhnAssistant Managing Director
- Mr. Gyu Hyeong ChoAssistant Managing Director
- Ms. Ji Seon ChoiAssistant Managing Director
- Mr. Sang Jin JeonAssistant Managing Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Samjin Pharmaceutical employs 776 full-time employees in Seoul, South Korea.
- Samjin's product portfolio includes antipyretics, analgesics, and antihistaminic agents.
- Samjin distributes pharmaceutical products to hospitals and drugstores across domestic and overseas markets.
Weaknesses
- Samjin's business is limited to the domestic market and overseas markets without specific country names.
- Samjin's product forms include tablets, injections, and capsules but lack innovative delivery systems.
- Samjin's product range covers antipyretics, analgesics, and antihistaminic agents but lacks specialty drugs.
Opportunities
- Samjin can expand into new markets like the United States and Europe for pharmaceutical distribution.
- Samjin can develop new products in the osteoporosis treatment segment.
- Samjin can target the growing global market for antineoplastic agents.
Threats
- Samjin faces competition from other Korean pharmaceutical companies in the domestic market.
- Samjin's reliance on the domestic market exposes it to economic fluctuations in South Korea.
- Samjin's product range does not include emerging treatments for chronic diseases.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.